Kinase Inhibitor Library Mini

83 Cited Publications
Kundenbewertung

Based on 83 publication(s) in Google Scholar

Kinases is a class of enzymes that adds chemicals called phosphates to other molecules, such as sugars or proteins. Protein phosphorylation serves as a critical regulatory mechanism for numerous cellular processes including cell division, metabolism, and signal transduction, with approximately 50% of cellular functions in humans being regulated by kinase activity. In drug discovery, kinases represent a major category of therapeutic targets, and kinase inhibitors constitute an important class of pharmaceuticals that block the activity of specific disease-associated enzymes, particularly in cancer and inflammatory disorders. Small molecule kinase inhibitors represent one of the fastest-growing drug categories, having received U.S. Food and Drug Administration (FDA) approval for both oncological and non-oncological indications. As of September 2023, over 70 FDA-approved small molecule kinase inhibitors are commercially available.

The MCE Kinase Inhibitor Library Mini contains 271 kinase inhibitors primarily targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.), and carbohydrate kinases. This collection includes 1-3 highly specific representative compounds per target, optimized for screening of kinase-related drug targets in pharmaceutical research.

For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, and 2 mM for compounds with solubility between 2 mM and 10 mM.

  • PDF
  • Excel
  • SDF
  • Manual

Service

Description & Advantages

•   A unique collection of 271 kinase inhibitors for high-throughput screening (HTS) and high-content screening (HCS).

•   The library contains compounds targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.) and carbohydrate kinases.

•   Kinase inhibitors have played an increasingly prominent role in the treatment of cancer and other diseases.

•   Bioactivity and safety confirmed by preclinical research and clinical trials. Some inhibitors have been approved by FDA.

•   Structurally diverse, medicinally active, and cell permeable.

•   Rich documentation with structure, IC50, and customer reviews.

•   NMR and HPLC validated to ensure high purity.

•   All compounds are in stock and continuously updated.

Product Details

Formulation

A collection of 271 kinase inhibitors supplied as pre-dissolved Solutions or Solid

Solution: 261 compounds supplied in 10 mM solution, 10 compounds supplied in 2 mM solution.

Layout

96-well storage tube or 96-well plate: 1st and 12th column are left empty.
384-well plate: the first two columns and the last two columns are left empty.
Compounds with different concentrations or dissolved in different solvents will be put on separate plates.
This way of layout may increase the number of plates because there could be three solvents and three concentrations.
If you have other requirements, please let us know.

Container

96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode

Storage
-80°C
Shipping
Blue ice or dry ice

Documentation

  • PDF
  • Excel
  • SDF
  • Manual

Composition

Get a Quotation Now Auf Lager

Please select quantity
Amount: USD 0.00
Size
Price
Stock
Operate
Sample (0.1mg)
Free
In-stock
Estimated to ship on August 31 More
Apply Now
200 mg
USD 120
In-stock
Estimated to ship on August 31 More
500 mg
Angebot einholen
Consult sales personnel for more information
Massenanfrage
200 mg
USD 120
In-stock
Estimated to ship on August 31 More
500 mg
Angebot einholen
Consult sales personnel for more information
Massenanfrage
500 mg
Angebot einholen
Consult sales personnel for more information
Bulk Inquiry
Estimated to ship on August 31 More